145
Participants
Start Date
October 17, 2019
Primary Completion Date
September 8, 2023
Study Completion Date
September 8, 2023
Pomalidomide Oral Product
Pomalidomide, a third generation derivative of thalidomide, given orally at a starting dose of 4 mg/day for days 1-28 of six 28-day cycles. The dose may be reduced to 3 or 2 mg/day based on specific adverse event (AE) criteria.
Placebo oral capsule
Matching placebo will be given.
University of Pennsylvania Perelman School of Medicine, Philadelphia
Johns Hopkins Hospital, Baltimore
University of North Carolina, Chapel Hill
University of Florida, Gainesville
University of Alabama at Birmingham, Birmingham
Cleveland Clinic, Cleveland
Medical College of Wiconsin, Milwaukee
University of Minnesota Health Clinical Research Unit, Minneapolis
Mayo Clinic, Rochester
Baylor College of Medicine, Texas Children's Hospital, Houston
University of Utah Healthcare, Salt Lake City
UCSD Hemophilia and Thrombosis Treatment Center, San Diego
UCSF Outpatient Hematology Clinic, San Francisco
Massachussets General Hospital, Boston
RTI International
OTHER
The Cleveland Clinic
OTHER